Hitachi Medical Systems formally launched its 1.2T vertical field open MR scanner at the RSNA meeting. Oasis, shown as a work-in-progress at last year’s meeting, cleared the FDA in September.
Hitachi Medical Systems formally launched its 1.2T vertical field open MR scanner at the RSNA meeting. Oasis, shown as a work-in-progress at last year's meeting, cleared the FDA in September. Built around a gradient system with 33 mT/m amplitude and 100 T/m/sec slew rate, the scanner features Zenith RF coils. These coils are the culmination of 20 years' experience in the development of vertical field MR, according to Hitachi. Field uniformity is driven by the company's proprietary Higher-Order Active Shim Technology, which is designed to ensure fat saturation over the scanner's large field-of-view. Oasis also features Hitachi's RAPID parallel imaging, TRAQ time-resolved MR angiography, and RADAR patient-motion compensating technology.
Hitachi is also unveiling a new pulse sequence for the cylindrical 1.5T Echelon scanner. The TIGRE sequence supports dynamic abdominal and bilateral breast studies at high temporal and spatial resolution.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.